Instruction 1(b).

FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, I	D.C. 20549	
---------------	------------	--

	STATEMENT OF CHANGES IN BENEFICIAL	<b>OWNERSHIP</b>
to Section 16. Form 4 or Form 5		
obligations may continue. See		

**OMB APPROVAL** 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  TRENARY C RUSSELL III					2. Issuer Name and Ticker or Trading Symbol Outlook Therapeutics, Inc. [ OTLK ]										ck all app	tor 10% Owner			
(Last) (First) (Middle) 485 ROUTE 1 SOUTH, BUILDING F SUITE 320					3. Date of Earliest Transaction (Month/Day/Year) 12/02/2021									X	X Officer (give title below) Other (specify below)  CEO and President				
(Street) ISELIN (City)	NJ (Sta										Line)	i. Individual or Joint/Group Filing (Check Applicable ine)  X Form filed by One Reporting Person  Form filed by More than One Reporting Person							
		Table	I - Noi	n-Deriva	tive S	Secu	rities	Acq	uired,	Dis	posed of	, or E	Benef	iciall	y Own	ed			
Date			2. Transac Date (Month/Da	Execution Date,		Date,	3. Transaction Code (Instr. 8) 4. Securities Disposed Of 5)					5. Amo Securit Benefic Owned Report	ties cially Following	Form (D) o	wnership n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
										Code V		(A) or (D)		rice	Transaction(s) (Instr. 3 and 4)				(5 4)
Common Stock 12/0			12/02/	2021				P		10,000		A	\$1.4	10,000			D		
		Tal									osed of, onvertib				Owne	d			
1. Title of Derivative Security (Instr. 3)	ative   Conversion   Date   Execution Date, rity   or Exercise   (Month/Day/Year)   if any			Transaction of Code (Instr. Derivative		vative irities ired r osed )	6. Date Exercisable and Expiration Date (Month/Day/Year)  Date Expiration		7. Title and Amount of Securities Underlying Derivative Security (Ins 3 and 4)  Amount or Numb of Title Share		Str.	Price of Privative Ecurity estr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	у	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)			

**Explanation of Responses:** 

Remarks:

/s/ Lawrence Kenyon, Attorney-in-Fact

12/02/2021

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.